STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 316,017 shares of the business's stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director owned
STAAR Surgical Company (NASDAQ: STAA - Get Free Report) Director Broadwood Partners, L.P. purchased 299,432 shares of the business's stock in a transaction on Thursday, March 12th. The shares were purchased at an average price of $18.12 per share, with a total value of $5,425,707.84. Following the completion of the purchase, the director owned 15,807,825 shares
STAAR Surgical Company (STAA) Q4 2025 Earnings Call Transcript
Staar Surgical (STAA) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to a loss of $0.5 per share a year ago.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR's results release can be found here: https://investors.staar.com/news-and-events/press-releases. Fellow Shareholders, This past month marked an important transition for our company as we stepped into the roles of Interi.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/news-and-events/press-releases. Fourth Quarter 2025 Financial Overview.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This achievement underscores the growing global preference for lens-based solutions in refractive vision correction as.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR S.
Merit Medical Systems (NASDAQ: MMSI - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends. Analyst Ratings This is a summary of
BCK Capital Management LP bought a new stake in shares of STAAR Surgical Company (NASDAQ: STAA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 51,006 shares of the medical instruments supplier's stock, valued at approximately $1,371,000. STAAR Surgical accounts
STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing.
Credit Industriel ET Commercial bought a new position in shares of STAAR Surgical Company (NASDAQ: STAA) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 121,258 shares of the medical instruments supplier's stock, valued at approximately $3,258,000. Credit Industriel ET Commercial owned approximately
ABC Arbitrage SA acquired a new position in STAAR Surgical Company (NASDAQ: STAA) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 246,829 shares of the medical instruments supplier's stock, valued at approximately $6,632,000. ABC Arbitrage SA owned 0.50% of
Versor Investments LP purchased a new stake in shares of STAAR Surgical Company (NASDAQ: STAA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 212,421 shares of the medical instruments supplier's stock, valued at approximately $5,708,000. STAAR Surgical makes up about 1.1% of
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the “Board”) has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work t.
Pro-Dex (NASDAQ: PDEX - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Profitability This table compares Pro-Dex and STAAR Surgical's
STAAR Surgical (NASDAQ: STAA - Get Free Report) and Lancer Orthodontics (OTCMKTS:LANZ - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk. Analyst Ratings This is a summary of recent
Pre-Market Stock Futures: The futures are trading higher as we get set to close out the week on a possible winning note, after a massive bounce-back rally on Thursday that saw all the major indices surge higher. The combination of a stiff 2-day sell-off, positive economic data showing inflation steady and trending lower this week,... Here Are Friday's Top Wall Street Analyst Research Calls: ConocoPhillips, Devon Energy, Garmin, Honeywell, HP, PepsiCo, Rocket Labs, Seagate, and More.